In a recent interview with CNBC, Brian Moynihan casually revealed that Bank of America spends over $250 million annually on GLP-1 medications for its employees. At first, this was hardly shocking. Large corporations invest large sums of money in healthcare. That is not new. However, when the bigger picture became apparent, that figure felt like a defiant act.
Employers are quietly pulling out of GLP-1 coverage for obesity throughout corporate America. In 2025, 72% of large employers offered these weight-loss drugs; by 2026, that number had dropped to 60%.
According to a recent Business Group on Health survey, 14% of employers have already discontinued coverage or intend to do so by 2027, citing an anticipated 9.2% increase in overall healthcare costs the following year. Earlier this year, PwC reduced it. This past July, Wegovy and Zepbound were eliminated from Cigna’s own employee health plan. It is obvious which way things are going, and Bank of America is moving in the opposite direction.
The bank currently spends more than $2 billion a year on healthcare for its approximately 211,000 employees. About 13% of that is made up of GLP-1s alone. Moynihan is aware that this is a significant portion of the budget. Interestingly, he doesn’t appear to be bothered. He stated, “We see a great impact on the employees,” but he went on to say that some of them might not even be aware of the long-term health benefits until years after they have left the company. That’s fine with him. “It’s the right thing to do for your teammates,” he replied.
In the current environment, that logic seems almost archaic. Nowadays, the majority of benefit discussions start with a spreadsheet. The reasoning behind GLP-1 cuts is simple: the medications are costly, demand is growing, and it is difficult to measure the long-term savings from improved employee health during a quarterly earnings call.
Some employers see an easy off-ramp because cash-pay options are now available through direct-to-consumer platforms for as little as $149 per month, a significant decrease from the $1,600 monthly price tag when Wegovy first launched in 2021. Employees can make their own payments. In addition to being less expensive, it also doesn’t go toward their deductibles, which subtly saves the business more money.
That off-ramp is not accepted by Bank of America. Additionally, it isn’t writing blank checks. Employees who want GLP-1 coverage for obesity must sign up for bank-sponsored lifestyle coaching and health management programs. It is necessary to validate clinical eligibility, including body mass index thresholds. Although it is structured, the policy is generous. The bank seems to be attempting to make the investment justifiable rather than merely altruistic.
In a few years, it’s still unclear if this strategy will appear costly or prophetic. The argument in favor of GLP-1 coverage is based in part on the notion that healthier workers result in lower downstream medical costs, such as fewer heart attacks, hospital stays, and lost productivity. Moynihan has reported a decrease in heart-related incidents among drug-using employees. Despite the difficulty of separating cause and effect in a workforce of over 200,000 employees, that is significant data.
It’s not just the dollar amount that makes the Bank of America story worthwhile. It’s what the ruling says about how employers see their responsibilities to employees and how long that perspective can endure in the face of growing expenses. In a recent survey, about 30% of workers stated they would change jobs in order to obtain GLP-1 coverage. That’s not just a healthcare argument; it’s a recruitment argument. Moynihan appears to comprehend that. “We do it because we want to be the great place to work,” he stated.
The true story is still developing, regardless of whether the rest of corporate America eventually adopts that viewpoint or whether financial pressure continues to pull coverage in the opposite direction. Bank of America is currently an anomaly. In terms of healthcare policy, outliers are typically either early or incorrect.
